Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Remdesivir Prescription in Pregnant Women Infected With Covid-19: A Report of Compassionate Use Publisher



Zafarbakhsh A1 ; Vaezi A2 ; Haghjooy Javanmard S3 ; Sabet F1 ; Dehghan M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Obstetrics and Gynecology, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Physiology, School of Medicine, Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Advanced Biomedical Research Published:2023


Abstract

Background: Coronavirus disease 2019 (COVID-19) is an infectious disease that the physiological changes in pregnancy can make pregnant patients more susceptible to more severe forms of this infection. Hence, the treatment of COVID-19 in pregnant women can be challenging. This study was designed to evaluate the safety and efficacy of Remdesivir in pregnant women with COVID-19. Materials and Methods: This study was conducted on 150 pregnant women with moderate to severe COVID-19 infection. Remdesivir was prescribed and continued for 5 or 10 days according to the patient's condition. Maternal and pregnancy outcomes and also recovery rates were evaluated. Moreover, additional variables were examined: age, gestational age, symptoms, O2 saturation and laboratory tests at admission, the interval between symptom initiation and admission to hospital and Remdesivir prescription, hospitalization days, and ICU admission. Results: The mean age was 32.37 years. Cough and dyspnea were the most prevalent symptoms (74% and 68.7%, respectively). At the time of admission, 79 (52.7%) women needed low-flow oxygen support, 67 (44.7%) needed high-flow oxygen support, and 4 (2.7%) were intubated. Fifty-four (36%) patients required ICU care. In patients who died (12 women), Remdesivir was prescribed later than those discharged (P value, 0.04). Patients with favorable pregnancy outcomes received Remdesivir earlier than those with unfavorable pregnancy outcomes (P value: 0.008). The recovery rate was 70% (89.9% in the low-flow oxygen, 50.7% in the NIPPV/high flow oxygen, and 0% in the intubated women). Conclusion: The results suggest that the early prescription of Remdesivir in pregnant women with moderate COVID-19 can improve the outcomes. © 2023 The Author(s). All rights reserved.
Other Related Docs
9. Different Prognosis Among Pregnant Patients With Covid-19 Infection, Journal of Isfahan Medical School (2020)
10. Bleeding Diathesis or Prothrombotic State, Which One Predict the Covid-19 Prognosis in Pregnancy?, Journal of Obstetrics, Gynecology and Cancer Research (2021)
11. New Corona Virus (Covid-19) Management in Pregnancy and Childbirth, Archives of Clinical Infectious Diseases (2020)
13. Epidemiology, Virology, Clinical Features, Diagnosis, and Treatment of Sars-Cov-2 Infection, Journal of Experimental and Clinical Medicine (Turkey) (2021)
16. Epidemiological Study of Covid-19 in Iran and the World: A Review Study, Infectious Disorders - Drug Targets (2022)
17. Covid‑19’S Effect in Pregnancy and Vertical Transmission: A Systematic Review, International Journal of Preventive Medicine (2024)
19. Impact of Covid-19 Infection on Neonatal Birth Outcomes, Journal of Tropical Pediatrics (2021)
21. A Comprehensive Review of Therapeutic Options for Covid-19, Ethiopian Journal of Health Development (2022)
32. Evidence-Based Prediction of Covid-19 Severity in Hospitalized Children, International journal of clinical practice (2022)
36. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)